This activity is intended for diabetologists/endocrinologists, ophthalmologists, family medicine/primary care clinicians, pediatricians, nurses, and other members of the health care team for children with type 2 diabetes who may be at risk for retinopathy or other ocular complications.
The goal of this activity is to describe the risk of developing diabetes-associated ocular complications among youth diagnosed with diabetes, based on a retrospective, population-based medical record review including all residents of Olmsted County, Minnesota, diagnosed with either type 1 diabetes or type 2 diabetes during a 50-year period.
Upon completion of this activity, participants will:
Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Medscape policies. Others involved in the planning of this activity have no relevant financial relationships.
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.
Medscape, LLC designates this enduring material for a maximum of 0.25
AMA PRA Category 1 Credit(s)™
. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Awarded 0.25 contact hour(s) of nursing continuing professional development for RNs and APNs; 0 contact hours are in the area of pharmacology.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print
out the tally as well as the certificates from the CME/CE Tracker.
*The credit that you receive is based on your user profile.
CME / ABIM MOC / CE Released: 1/21/2022
Valid for credit through: 1/21/2023, 11:59 PM EST
processing....
Diabetes is a prevalent, chronic childhood disease associated with chronic hyperglycemia and end-organ damage often causing the microvascular triad of nephropathy, neuropathy, and retinopathy. Subsequent retinal neurodegeneration and blood-retinal barrier breakdown lead to diabetic retinopathy, the leading cause of blindness in working-age and young adults.
Children diagnosed with type 2 diabetes (T2D) appear significantly more likely to develop retinopathy and other ocular complications over time than children who are diagnosed with type 1 diabetes (T1D), researchers report.
Among a population-based cohort of children (defined as younger than 22 years), the risk for diabetic retinopathy was 88% greater in those with T2D than those with T1D within the first 15 years of disease diagnosis.
"The purpose of this study was to assess the risk of developing diabetes-associated ocular complications...among a population-based cohort of children diagnosed with either T1D or T2D during a 50-year period," lead author Patricia Bai, from the Mayo Clinic, Phoenix, Arizona, and colleagues reported in JAMA Ophthalmology.[1]
The researchers retrospectively reviewed medical records from all residents of Olmsted County, Minnesota, from 1970 to 2019. The study cohort included 606 children with a confirmed a diagnosis of T1D or T2D, 525 (86.6%) of whom had at least 1 ocular examination.
The mean age at diabetes diagnosis was 12.1 years (standard deviation, 5.4 years); most participants were White (95.7% in 1990), and half (50.3%) were male. Diabetes-associated ocular complications occurred in 31.9% and 26.6% of children with T1D and T2D, respectively.
The hazard ratios illustrating the risk between T2D and T1D rates were 1.88 (95% confidence interval [CI], 1.13-3.12; P=.02) for any diabetic retinopathy, 2.33 (95% CI, 0.99-5.50; P=.048) for proliferative diabetic retinopathy (PDR), 1.49 (95% CI, 0.46-4.89; P=.50) for diabetic macular edema, 2.43 (95% CI, 0.54-11.07; P=.24) for a visually significant cataract, and 4.06 (95% CI, 1.34-12.33; P=.007) for requiring pars plana vitrectomy (PPV) within the first 15 years of diagnosis.
These results suggest that earlier surveillance and intervention may help prevent vision-threatening complications, the researchers explained.
"After adjusting for race using self-identified categories of White or not White, the adjusted HR of developing any retinopathy was 1.63 (95% CI, 0.96-2.79; P = .07), and the adjusted [hazard ratio] of developing PDR was 2.02 (95% CI, 0.79-5.16; P = .14)" in patients with T2D versus T1D, the researchers wrote.
"We would expect the reported rate of type 2 diabetes to be potentially underestimated in our study cohort," Bai commented in an interview. "Race has been suggested to be a surrogate for other social determinants of health, such as lower rates of optimal follow-up care received by racial and ethnic minorities, which could influence subsequent retinopathy rates."
Understanding Retinopathy Outcomes in YouthIn an accompanying editorial, Jennifer K. Sun, MD, MPH, from Harvard Medical School, Boston, wrote that the present study indicates that the natural history of retinopathy may differ between patients with T1D and T2D.[2]
Although the pathophysiology of diabetic retinopathy in T1D and T2D appears similar, other patient-related factors such as lipid profiles, the presence of hypertension, and body mass index may differ between the 2 disease states.
She wrote that "there is a particular need to document retinopathy outcomes and risk factors for advanced disease in youth with T2D, for whom there is a paucity of information."
Bai and colleagues acknowledged that a key limitation of the study was the retrospective design. As a result, irregular follow-up and incomplete data may limit the applicability of the findings.
"Some children with milder forms of diabetes may have eluded detection, a limitation that is more likely to affect T2D, which may exist undetected for years before a diagnosis," Bai explained.
Dr Sun recommended that further epidemiologic studies are needed to help optimize guidelines for screening and follow-up for young people diagnosed with diabetes. "Such efforts may potentially lead to increased understanding of the mechanistic differences between pathology in T1D versus T2D," she concluded.
This study used the resources of the Rochester Epidemiology Project (REP) medical records linkage system, which is supported by grant funding from the National Institute on Aging, the Mayo Clinic Research Committee, and by fees paid annually by REP users. The study authors have disclosed no relevant financial relationships.
JAMA Ophthalmol. Published online December 2, 2021.